Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01608594 | Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma | completed | Phase 1 | 30 | Diwakar DavarOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01636960 | A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT03297463 | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT01341496 | Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | terminated | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02839694 | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 5, 2018 | clinicaltrials |
| NCT02166255 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00074308 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2018 | clinicaltrials |
| NCT02696356 | Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma | completed | Phase 1 | 18 | BrightPath BiotherapeuticsINDUSTRY | 1 | Jun 14, 2018 | clinicaltrials |
| NCT02138292 | A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma | completed | Phase 1 | 27 | University of Texas Southwestern Medical CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT02915666 | A Clinical Trial of Patients With Melanoma | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT01893099 | Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | completed | Phase 1 | 11 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | withdrawn | Phase 1 / Phase 2 | 0 | Joanne JeterOTHER | 0 | Apr 5, 2018 | clinicaltrials |
| NCT01943422 | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma(12-107) | completed | Phase 1 | 7 | John KirkwoodOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02668536 | A Sunscreen Based on Bioadhesive Nanoparticles | completed | Phase 1 | 13 | Yale UniversityOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT02870244 | Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | recruiting | Phase 1 | 18 | Loyola UniversityOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00056134 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 23 | University Hospital ErlangenOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02613325 | fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01079741 | Safety Study of Adjuvant Vaccine to Treat Melanoma Patients | completed | Phase 1 / Phase 2 | 34 | Nina BhardwajOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT01711684 | Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) | completed | Phase 1 | 6 | Rockefeller UniversityOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT02719015 | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02441465 | Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00715793 | Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma(UPCI-07-008) | completed | Phase 1 / Phase 2 | 39 | Hussein TawbiOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT02574533 | Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma | completed | Phase 1 | 2 | Gradalis, Inc.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00390338 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 | 22 | Pawel KalinskiOTHER | 1 | Sep 26, 2017 | clinicaltrials |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01622933 | Multiple Antigen-Engineered DC Vaccine for Melanoma | completed | Phase 1 | 35 | Lisa H. Butterfield, Ph.D.OTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT02935790 | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | completed | Phase 1 | 1 | CelgeneINDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00405587 | Safety Study of PLX4032 in Patients With Solid Tumors | completed | Phase 1 | 109 | PlexxikonINDUSTRY | 2 | Aug 22, 2017 | clinicaltrials |
| NCT01138410 | Study of a DNA Immunotherapy to Treat Melanoma | terminated | Phase 1 / Phase 2 | 35 | Scancell LtdINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00743496 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | completed | Phase 1 | 50 | St. Jude Children's Research HospitalOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01001299 | A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma | completed | Phase 1 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT02489266 | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 27, 2017 | clinicaltrials |
| NCT01067066 | A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | terminated | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 21, 2017 | clinicaltrials |
| NCT00062036 | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 33 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | terminated | Phase 1 / Phase 2 | 39 | University of IowaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00471471 | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 22 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00125749 | Vaccination of Patients With Stage IV Melanoma With Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00631072 | In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer | completed | Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00457418 | High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) | completed | Phase 1 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2018source: clinicaltrials